Triptorelin: Difference between revisions
m Protected "Triptorelin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
| Line 24: | Line 24: | ||
* ''GnRH analogues—agonists and antagonists'' A.M. Padula, | * ''GnRH analogues—agonists and antagonists'' A.M. Padula, | ||
University of Melbourne [http://dx.doi.org/10.1016/j.anireprosci.2005.05.005] | University of Melbourne [http://dx.doi.org/10.1016/j.anireprosci.2005.05.005] | ||
{{Sex hormones}} | {{Sex hormones}} | ||
[[Category:GnRH agonists]] | [[Category:GnRH agonists]] | ||
Revision as of 17:07, 20 August 2012
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Implant |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Excretion | Renal |
| Identifiers | |
| CAS Number | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C64H82N18O13 |
| Molar mass | 1311.5 g/mol |
|
WikiDoc Resources for Triptorelin |
|
Articles |
|---|
|
Most recent articles on Triptorelin Most cited articles on Triptorelin |
|
Media |
|
Powerpoint slides on Triptorelin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Triptorelin at Clinical Trials.gov Clinical Trials on Triptorelin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Triptorelin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Triptorelin Discussion groups on Triptorelin Patient Handouts on Triptorelin Directions to Hospitals Treating Triptorelin Risk calculators and risk factors for Triptorelin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Triptorelin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Triptorelin (acetate or palmoate) is a gonadotropin releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. Triptorelin is marketed under the brand names Decapeptyl® (Ferring Pharmaceuticals) and Diphereline® and Gonapeptyl®.
Triptorelin is sold by Pfizer in the United States as Trelstar®.
During the treatment of prostate cancer it does cause a surge of testosterone (an initial uplevel of testosterone levels). In men a reduction of serum testosterone levels into the range normally seen after surgical castration occurs appr. 2 to 4 weeks after initiation of therapy. In contrast gonadotropin releasing hormone Receptor antagonists does not cause a surge, but a sudden shut-down of testosterone level.
Systematic IUPAC Name: [d-Trp6]GnRH
References
- Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000 Jul;13 Suppl 1:723-37. Review. PMID 10969915
- GnRH analogues—agonists and antagonists A.M. Padula,
University of Melbourne [1]
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- GnRH agonists
- Endocrinology